Zattoni Fabio, Bednarova Iliana, Morlacco Alessandro, Motterle Giovanni, Beltrami Paolo, Dal Moro Fabrizio, Karnes R Jeffrey
Urology Unit, Academical Medical Centre Hospital, Udine, Italy.
Division of Radiology, Gorizia Hospital, Gorizia, Italy.
Cent European J Urol. 2020;73(4):445-456. doi: 10.5173/ceju.2020.0168.R1. Epub 2020 Dec 9.
Transitional cell carcinoma recurrence within an intestinal urinary diversion (TCCUD) after radical cystectomy (RC) is a rare condition with unknown origin, prognosis and treatment. The aim of this study was to describe treatment options and oncologic outcomes of this understudied site of recurrence in a multi-institutional case series.
TCCUD relapse cases after RC were investigated in a retrospective, multi-institutional study. Surgical approach and adjuvant chemotherapy were discussed. Early and late complications were described according to the Clavien-Dindo classification. Kaplan-Meier method was used to assess progression-free and cancer-specific survival.
A total of 19 patients were selected. The most common presentation was gross hematuria. The median interval between RC and TCCUD was 51.2 months. Fifteen patients (78.9%) underwent surgical excision, and two underwent concomitant radical nephroureterectomy. In 12 (63.1%) cases the site of TCCUD was the uretero-ileal anastomosis. Tumor invading the muscularis of the intestinal diversion was described in 10 (52.6%) cases. Surgical complications occurred in 7/15 (46.6%) patients, of these two with Clavien-Dindo Grade III. Four patients (21.0%) underwent adjuvant chemotherapy and two (10.5%) both chemotherapy and radiation therapy. During follow-up 15 patients (78.9%) presented with other sites of recurrence, with lymph nodes (21.0%) and liver (15.7%) being the most common localizations. Recurrence free and overall survival rates were 36.8% and 15.8%, and 56.5% and 24.2%, respectively at 12 and 18 months.
Most patients with TCCUD have invasive disease and a substantial percentage experience upper tract cancer during their disease course. TCCUD is often the herald of advanced disease and systemic progression, with poor progression-free and overall survival rates.
根治性膀胱切除术后肠道代膀胱内移行细胞癌复发(TCCUD)是一种罕见疾病,其起源、预后和治疗均不明确。本研究旨在描述在多机构病例系列中,这种研究较少的复发部位的治疗选择和肿瘤学结局。
在一项回顾性多机构研究中,对根治性膀胱切除术后TCCUD复发病例进行调查。讨论了手术方法和辅助化疗。根据Clavien-Dindo分类描述早期和晚期并发症。采用Kaplan-Meier方法评估无进展生存期和癌症特异性生存期。
共纳入19例患者。最常见的表现是肉眼血尿。根治性膀胱切除术与TCCUD的中位间隔时间为51.2个月。15例患者(78.9%)接受了手术切除,2例同时接受了根治性肾输尿管切除术。12例(63.1%)TCCUD发生在输尿管-回肠吻合口。10例(52.6%)病例描述肿瘤侵犯肠道代膀胱肌层。7/15例(46.6%)患者发生手术并发症,其中2例为Clavien-Dindo III级。4例患者(21.0%)接受了辅助化疗,2例(10.5%)同时接受了化疗和放疗。随访期间,15例患者(78.9%)出现其他复发部位,最常见的是淋巴结(21.0%)和肝脏(15.7%)。12个月和18个月时的无复发生存率和总生存率分别为36.8%和15.8%,以及56.5%和24.2%。
大多数TCCUD患者患有浸润性疾病,相当比例的患者在病程中发生上尿路癌。TCCUD通常是晚期疾病和全身进展的先兆,无进展生存期和总生存率较差。